Bepirovirsen not checked

GSK · GSK3228836 · ISIS 505358

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2 trial completes
Trials
6 active
17 in total · 6 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“No study medication will be administered in this study. Eligible participants who received bepirovirsen in the parent studies will be included.”In the company’s words, NCT07908459 on ClinicalTrials.gov
Tested for
Hepatitis B (6 trials), Chronic Hepatitis B Virus Infection
Main trialPhase 4
“This multi-country, longitudinal follow-up study will enrol adults with chronic hepatitis B (CHB) who previously participated in the Phase III B-Well-1 ((202009: NCT05630807) or B-Well-2 (219288: NCT05630820) studies, received 24 weeks of Bepirovirsen treatment, and achieved hepatitis B surface antigen (HBsAg) levels less than or equal to (\<=) 100 International units per millilitres (IU/mL) at Week 72 without achieving functional cure. No investigational treatment will be administered in this study. Participants will be followed approximately every 6 months for up to 4 years, and…”In the company’s words, NCT07908459 on ClinicalTrials.gov
Other names
GSK3228836 · IONIS-HBVRx · ISIS 505358

Other drugs for Hepatitis B

All 41 drugs for Hepatitis B

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials17

TrialPhaseCompletesWhat it tests
Phase 4Not yet recruiting 3 Dec 2030 B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants
Phase 2Active, not recruiting 22 Apr 2027 Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
Phase 2Active, not recruiting 31 May 2027 A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
Phase 2Active, not recruiting 24 Jan 2029 Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
Phase 1Active, not recruiting 3 Mar 2026 A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease
Phase 1Not yet recruiting 30 Mar 2027 A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants
Phase 3Completed 3 Nov 2025 Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
Phase 3Completed 11 Nov 2025 Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
Phase 2Completed 18 Dec 2019 Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection
Phase 2Completed 18 Mar 2022 A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)
Phase 2Completed 17 Feb 2023 Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)
Phase 2Completed 30 Nov 2023 A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B
Phase 2Completed 5 Aug 2025 A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy
Phase 1/2Terminated 19 May 2025 Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
Phase 1Completed 12 May 2022 Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
Phase 1Completed 3 May 2024 A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants
Phase 1Completed 28 Apr 2025 Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow Bepirovirsen

Following is part of Solo: you see every change to Bepirovirsen the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in